Multiple Sclerosis Drugs - Poland

Poland

The Multiple Sclerosis Drugs market in Poland is expected to witness a significant revenue growth, with projections indicating that it will reach US$65.52m in 2024.
Furthermore, the market is expected to experience a steady annual growth rate of 0.87% between 2024 and 2029, resulting in a market volume of US$68.42m by 2029.
When compared globally, it is noteworthy that United States will generate the highest revenue, amounting to US$11,770.00m in 2024.
This demonstrates the dominance of the US market in the Multiple Sclerosis Drugs market.
In Poland, the demand for innovative multiple sclerosis drugs is growing rapidly due to the increasing prevalence of the disease and the government's efforts to improve access to advanced treatments.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Multiple Sclerosis Drugs in Poland has been on the rise in the past few years.

Customer preferences: Patients in Poland prefer disease-modifying therapies (DMTs) over symptomatic treatments due to the long-term benefits of DMTs. The preference for DMTs has led to an increase in the demand for injectable drugs, such as interferons and glatiramer acetate, which are widely used in Poland.

Trends in the market: The Multiple Sclerosis Drugs market in Poland has been growing due to the increasing prevalence of the disease. Poland has one of the highest rates of multiple sclerosis (MS) in Europe, with around 80,000 people affected. This has led to an increase in the demand for MS drugs. Additionally, the introduction of new drugs with improved efficacy and safety profiles has also contributed to the growth of the market.

Local special circumstances: The Polish government provides reimbursement for MS drugs, which has made them more accessible to patients. However, the reimbursement process can be lengthy and bureaucratic, which can be a barrier to access for some patients. Additionally, there is a shortage of neurologists in Poland, which can lead to delays in diagnosis and treatment.

Underlying macroeconomic factors: Poland has a growing economy, which has led to an increase in healthcare spending. The government has also made efforts to improve the healthcare system, which has contributed to the growth of the MS drugs market. However, the COVID-19 pandemic has had an impact on the market, with some patients experiencing delays in treatment due to healthcare system disruptions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.